Global CAR-T Therapy for Hematological Cancer Market Growth (Status and Outlook) 2025-2031--LP INFORMATION, INC.

Global CAR-T Therapy for Hematological Cancer Market Growth (Status and Outlook) 2025-2031

Product Code: 1562450

Industry: Pharma & Healthcare

Published: May 15,2025

Pages: 98

Delivery Time: 2-3 business days

Global CAR-T Therapy for Hematological Cancer Market Growth (Status and Outlook) 2025-2031

Product Code: 1562450

Industry: Pharma & Healthcare

Published: May 15,2025

Pages: 98

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

According to this study, the global CAR-T Therapy for Hematological Cancer market size will reach US$ 22200 million by 2031.

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a cutting-edge immunotherapy for hematological cancers, involving the genetic modification of a patient’s T cells to express synthetic receptors targeting specific antigens on cancer cells. These engineered T cells are expanded in the lab and reintroduced into the patient, where they can recognize and destroy cancerous cells with high specificity. Key features include its remarkable efficacy in treating certain blood cancers like B-cell lymphomas, leukemias, and multiple myeloma, particularly in patients with relapsed or refractory disease, and its potential for long-term remission. CAR-T therapy is primarily applied in advanced hematological malignancies and is being explored for broader indications through ongoing clinical trials. Despite its promise, challenges such as high cost, manufacturing complexity, and management of severe side effects like cytokine release syndrome (CRS) remain areas of active research.

United States market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key CAR-T Therapy for Hematological Cancer players cover Novartis, Gilead Sciences, Bristol-Myers Squibb, J&J, JW Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “CAR-T Therapy for Hematological Cancer Industry Forecast” looks at past sales and reviews total world CAR-T Therapy for Hematological Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy for Hematological Cancer sales for 2025 through 2031. With CAR-T Therapy for Hematological Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy for Hematological Cancer industry.

This Insight Report provides a comprehensive analysis of the global CAR-T Therapy for Hematological Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR-T Therapy for Hematological Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-T Therapy for Hematological Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy for Hematological Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy for Hematological Cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy for Hematological Cancer market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Target: CD19

    Target: BCMA

    Others

Segmentation by Application:

    Lymphoma

    Multiple Myeloma

    Leukemia

This report also splits the market by region:

    Americas

    United States

    Canada

    Mexico

    Brazil

    APAC

    China

    Japan

    Korea

    Southeast Asia

    India

    Australia

    Europe

    Germany

    France

UK

    Italy

    Russia

    Middle East & Africa

    Egypt

    South Africa

    Israel

    Turkey

    GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Novartis

    Gilead Sciences

    Bristol-Myers Squibb

J&J

    JW Therapeutics

    FOSUNKite

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global CAR-T Therapy for Hematological Cancer Market Size (2020-2031)
        2.1.2 CAR-T Therapy for Hematological Cancer Market Size CAGR by Region (2020 VS 2024 VS 2031)
        2.1.3 World Current & Future Analysis for CAR-T Therapy for Hematological Cancer by Country/Region (2020, 2024 & 2031)
    2.2 CAR-T Therapy for Hematological Cancer Segment by Type
        2.2.1 Target: CD19
        2.2.2 Target: BCMA
        2.2.3 Others
    2.3 CAR-T Therapy for Hematological Cancer Market Size by Type
        2.3.1 CAR-T Therapy for Hematological Cancer Market Size CAGR by Type (2020 VS 2024 VS 2031)
        2.3.2 Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2020-2025)
    2.4 CAR-T Therapy for Hematological Cancer Segment by Application
        2.4.1 Lymphoma
        2.4.2 Multiple Myeloma
        2.4.3 Leukemia
    2.5 CAR-T Therapy for Hematological Cancer Market Size by Application
        2.5.1 CAR-T Therapy for Hematological Cancer Market Size CAGR by Application (2020 VS 2024 VS 2031)
        2.5.2 Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2020-2025)

3 CAR-T Therapy for Hematological Cancer Market Size by Player
    3.1 CAR-T Therapy for Hematological Cancer Market Size Market Share by Player
        3.1.1 Global CAR-T Therapy for Hematological Cancer Revenue by Player (2020-2025)
        3.1.2 Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Player (2020-2025)
    3.2 Global CAR-T Therapy for Hematological Cancer Key Players Head office and Products Offered
    3.3 Market Concentration Rate Analysis
        3.3.1 Competition Landscape Analysis
        3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.4 New Products and Potential Entrants
    3.5 Mergers & Acquisitions, Expansion

4 CAR-T Therapy for Hematological Cancer by Region
    4.1 CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025)
    4.2 Global CAR-T Therapy for Hematological Cancer Annual Revenue by Country/Region (2020-2025)
    4.3 Americas CAR-T Therapy for Hematological Cancer Market Size Growth (2020-2025)
    4.4 APAC CAR-T Therapy for Hematological Cancer Market Size Growth (2020-2025)
    4.5 Europe CAR-T Therapy for Hematological Cancer Market Size Growth (2020-2025)
    4.6 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size Growth (2020-2025)

5 Americas
    5.1 Americas CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025)
    5.2 Americas CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025)
    5.3 Americas CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025)
    6.2 APAC CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025)
    6.3 APAC CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia

7 Europe
    7.1 Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025)
    7.2 Europe CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025)
    7.3 Europe CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa CAR-T Therapy for Hematological Cancer by Region (2020-2025)
    8.2 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025)
    8.3 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Global CAR-T Therapy for Hematological Cancer Market Forecast
    10.1 Global CAR-T Therapy for Hematological Cancer Forecast by Region (2026-2031)
        10.1.1 Global CAR-T Therapy for Hematological Cancer Forecast by Region (2026-2031)
        10.1.2 Americas CAR-T Therapy for Hematological Cancer Forecast
        10.1.3 APAC CAR-T Therapy for Hematological Cancer Forecast
        10.1.4 Europe CAR-T Therapy for Hematological Cancer Forecast
        10.1.5 Middle East & Africa CAR-T Therapy for Hematological Cancer Forecast
    10.2 Americas CAR-T Therapy for Hematological Cancer Forecast by Country (2026-2031)
        10.2.1 United States Market CAR-T Therapy for Hematological Cancer Forecast
        10.2.2 Canada Market CAR-T Therapy for Hematological Cancer Forecast
        10.2.3 Mexico Market CAR-T Therapy for Hematological Cancer Forecast
        10.2.4 Brazil Market CAR-T Therapy for Hematological Cancer Forecast
    10.3 APAC CAR-T Therapy for Hematological Cancer Forecast by Region (2026-2031)
        10.3.1 China CAR-T Therapy for Hematological Cancer Market Forecast
        10.3.2 Japan Market CAR-T Therapy for Hematological Cancer Forecast
        10.3.3 Korea Market CAR-T Therapy for Hematological Cancer Forecast
        10.3.4 Southeast Asia Market CAR-T Therapy for Hematological Cancer Forecast
        10.3.5 India Market CAR-T Therapy for Hematological Cancer Forecast
        10.3.6 Australia Market CAR-T Therapy for Hematological Cancer Forecast
    10.4 Europe CAR-T Therapy for Hematological Cancer Forecast by Country (2026-2031)
        10.4.1 Germany Market CAR-T Therapy for Hematological Cancer Forecast
        10.4.2 France Market CAR-T Therapy for Hematological Cancer Forecast
        10.4.3 UK Market CAR-T Therapy for Hematological Cancer Forecast
        10.4.4 Italy Market CAR-T Therapy for Hematological Cancer Forecast
        10.4.5 Russia Market CAR-T Therapy for Hematological Cancer Forecast
    10.5 Middle East & Africa CAR-T Therapy for Hematological Cancer Forecast by Region (2026-2031)
        10.5.1 Egypt Market CAR-T Therapy for Hematological Cancer Forecast
        10.5.2 South Africa Market CAR-T Therapy for Hematological Cancer Forecast
        10.5.3 Israel Market CAR-T Therapy for Hematological Cancer Forecast
        10.5.4 Turkey Market CAR-T Therapy for Hematological Cancer Forecast
    10.6 Global CAR-T Therapy for Hematological Cancer Forecast by Type (2026-2031)
    10.7 Global CAR-T Therapy for Hematological Cancer Forecast by Application (2026-2031)
        10.7.1 GCC Countries Market CAR-T Therapy for Hematological Cancer Forecast

11 Key Players Analysis
    11.1 Novartis
        11.1.1 Novartis Company Information
        11.1.2 Novartis CAR-T Therapy for Hematological Cancer Product Offered
        11.1.3 Novartis CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2020-2025)
        11.1.4 Novartis Main Business Overview
        11.1.5 Novartis Latest Developments
    11.2 Gilead Sciences
        11.2.1 Gilead Sciences Company Information
        11.2.2 Gilead Sciences CAR-T Therapy for Hematological Cancer Product Offered
        11.2.3 Gilead Sciences CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2020-2025)
        11.2.4 Gilead Sciences Main Business Overview
        11.2.5 Gilead Sciences Latest Developments
    11.3 Bristol-Myers Squibb
        11.3.1 Bristol-Myers Squibb Company Information
        11.3.2 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Product Offered
        11.3.3 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2020-2025)
        11.3.4 Bristol-Myers Squibb Main Business Overview
        11.3.5 Bristol-Myers Squibb Latest Developments
    11.4 J&J
        11.4.1 J&J Company Information
        11.4.2 J&J CAR-T Therapy for Hematological Cancer Product Offered
        11.4.3 J&J CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2020-2025)
        11.4.4 J&J Main Business Overview
        11.4.5 J&J Latest Developments
    11.5 JW Therapeutics
        11.5.1 JW Therapeutics Company Information
        11.5.2 JW Therapeutics CAR-T Therapy for Hematological Cancer Product Offered
        11.5.3 JW Therapeutics CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2020-2025)
        11.5.4 JW Therapeutics Main Business Overview
        11.5.5 JW Therapeutics Latest Developments
    11.6 FOSUNKite
        11.6.1 FOSUNKite Company Information
        11.6.2 FOSUNKite CAR-T Therapy for Hematological Cancer Product Offered
        11.6.3 FOSUNKite CAR-T Therapy for Hematological Cancer Revenue, Gross Margin and Market Share (2020-2025)
        11.6.4 FOSUNKite Main Business Overview
        11.6.5 FOSUNKite Latest Developments

12 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. CAR-T Therapy for Hematological Cancer Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
 Table 2. CAR-T Therapy for Hematological Cancer Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
 Table 3. Major Players of Target: CD19
 Table 4. Major Players of Target: BCMA
 Table 5. Major Players of Others
 Table 6. CAR-T Therapy for Hematological Cancer Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
 Table 7. Global CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025) & ($ millions)
 Table 8. Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2020-2025)
 Table 9. CAR-T Therapy for Hematological Cancer Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
 Table 10. Global CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025) & ($ millions)
 Table 11. Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2020-2025)
 Table 12. Global CAR-T Therapy for Hematological Cancer Revenue by Player (2020-2025) & ($ millions)
 Table 13. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Player (2020-2025)
 Table 14. CAR-T Therapy for Hematological Cancer Key Players Head office and Products Offered
 Table 15. CAR-T Therapy for Hematological Cancer Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
 Table 16. New Products and Potential Entrants
 Table 17. Mergers & Acquisitions, Expansion
 Table 18. Global CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025) & ($ millions)
 Table 19. Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Region (2020-2025)
 Table 20. Global CAR-T Therapy for Hematological Cancer Revenue by Country/Region (2020-2025) & ($ millions)
 Table 21. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Country/Region (2020-2025)
 Table 22. Americas CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025) & ($ millions)
 Table 23. Americas CAR-T Therapy for Hematological Cancer Market Size Market Share by Country (2020-2025)
 Table 24. Americas CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025) & ($ millions)
 Table 25. Americas CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2020-2025)
 Table 26. Americas CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025) & ($ millions)
 Table 27. Americas CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2020-2025)
 Table 28. APAC CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025) & ($ millions)
 Table 29. APAC CAR-T Therapy for Hematological Cancer Market Size Market Share by Region (2020-2025)
 Table 30. APAC CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025) & ($ millions)
 Table 31. APAC CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025) & ($ millions)
 Table 32. Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025) & ($ millions)
 Table 33. Europe CAR-T Therapy for Hematological Cancer Market Size Market Share by Country (2020-2025)
 Table 34. Europe CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025) & ($ millions)
 Table 35. Europe CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025) & ($ millions)
 Table 36. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025) & ($ millions)
 Table 37. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025) & ($ millions)
 Table 38. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025) & ($ millions)
 Table 39. Key Market Drivers & Growth Opportunities of CAR-T Therapy for Hematological Cancer
 Table 40. Key Market Challenges & Risks of CAR-T Therapy for Hematological Cancer
 Table 41. Key Industry Trends of CAR-T Therapy for Hematological Cancer
 Table 42. Global CAR-T Therapy for Hematological Cancer Market Size Forecast by Region (2026-2031) & ($ millions)
 Table 43. Global CAR-T Therapy for Hematological Cancer Market Size Market Share Forecast by Region (2026-2031)
 Table 44. Global CAR-T Therapy for Hematological Cancer Market Size Forecast by Type (2026-2031) & ($ millions)
 Table 45. Global CAR-T Therapy for Hematological Cancer Market Size Forecast by Application (2026-2031) & ($ millions)
 Table 46. Novartis Details, Company Type, CAR-T Therapy for Hematological Cancer Area Served and Its Competitors
 Table 47. Novartis CAR-T Therapy for Hematological Cancer Product Offered
 Table 48. Novartis CAR-T Therapy for Hematological Cancer Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 49. Novartis Main Business
 Table 50. Novartis Latest Developments
 Table 51. Gilead Sciences Details, Company Type, CAR-T Therapy for Hematological Cancer Area Served and Its Competitors
 Table 52. Gilead Sciences CAR-T Therapy for Hematological Cancer Product Offered
 Table 53. Gilead Sciences CAR-T Therapy for Hematological Cancer Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 54. Gilead Sciences Main Business
 Table 55. Gilead Sciences Latest Developments
 Table 56. Bristol-Myers Squibb Details, Company Type, CAR-T Therapy for Hematological Cancer Area Served and Its Competitors
 Table 57. Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Product Offered
 Table 58. Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 59. Bristol-Myers Squibb Main Business
 Table 60. Bristol-Myers Squibb Latest Developments
 Table 61. J&J Details, Company Type, CAR-T Therapy for Hematological Cancer Area Served and Its Competitors
 Table 62. J&J CAR-T Therapy for Hematological Cancer Product Offered
 Table 63. J&J CAR-T Therapy for Hematological Cancer Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 64. J&J Main Business
 Table 65. J&J Latest Developments
 Table 66. JW Therapeutics Details, Company Type, CAR-T Therapy for Hematological Cancer Area Served and Its Competitors
 Table 67. JW Therapeutics CAR-T Therapy for Hematological Cancer Product Offered
 Table 68. JW Therapeutics CAR-T Therapy for Hematological Cancer Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 69. JW Therapeutics Main Business
 Table 70. JW Therapeutics Latest Developments
 Table 71. FOSUNKite Details, Company Type, CAR-T Therapy for Hematological Cancer Area Served and Its Competitors
 Table 72. FOSUNKite CAR-T Therapy for Hematological Cancer Product Offered
 Table 73. FOSUNKite CAR-T Therapy for Hematological Cancer Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 74. FOSUNKite Main Business
 Table 75. FOSUNKite Latest Developments


List of Figures
 Figure 1. CAR-T Therapy for Hematological Cancer Report Years Considered
 Figure 2. Research Objectives
 Figure 3. Research Methodology
 Figure 4. Research Process and Data Source
 Figure 5. Global CAR-T Therapy for Hematological Cancer Market Size Growth Rate (2020-2031) ($ millions)
 Figure 6. CAR-T Therapy for Hematological Cancer Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Figure 7. CAR-T Therapy for Hematological Cancer Sales Market Share by Country/Region (2024)
 Figure 8. CAR-T Therapy for Hematological Cancer Sales Market Share by Country/Region (2020, 2024 & 2031)
 Figure 9. Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Type in 2024
 Figure 10. CAR-T Therapy for Hematological Cancer in Lymphoma
 Figure 11. Global CAR-T Therapy for Hematological Cancer Market: Lymphoma (2020-2025) & ($ millions)
 Figure 12. CAR-T Therapy for Hematological Cancer in Multiple Myeloma
 Figure 13. Global CAR-T Therapy for Hematological Cancer Market: Multiple Myeloma (2020-2025) & ($ millions)
 Figure 14. CAR-T Therapy for Hematological Cancer in Leukemia
 Figure 15. Global CAR-T Therapy for Hematological Cancer Market: Leukemia (2020-2025) & ($ millions)
 Figure 16. Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Application in 2024
 Figure 17. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Player in 2024
 Figure 18. Global CAR-T Therapy for Hematological Cancer Market Size Market Share by Region (2020-2025)
 Figure 19. Americas CAR-T Therapy for Hematological Cancer Market Size 2020-2025 ($ millions)
 Figure 20. APAC CAR-T Therapy for Hematological Cancer Market Size 2020-2025 ($ millions)
 Figure 21. Europe CAR-T Therapy for Hematological Cancer Market Size 2020-2025 ($ millions)
 Figure 22. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size 2020-2025 ($ millions)
 Figure 23. Americas CAR-T Therapy for Hematological Cancer Value Market Share by Country in 2024
 Figure 24. United States CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 25. Canada CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 26. Mexico CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 27. Brazil CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 28. APAC CAR-T Therapy for Hematological Cancer Market Size Market Share by Region in 2024
 Figure 29. APAC CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2020-2025)
 Figure 30. APAC CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2020-2025)
 Figure 31. China CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 32. Japan CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 33. South Korea CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 34. Southeast Asia CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 35. India CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 36. Australia CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 37. Europe CAR-T Therapy for Hematological Cancer Market Size Market Share by Country in 2024
 Figure 38. Europe CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2020-2025)
 Figure 39. Europe CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2020-2025)
 Figure 40. Germany CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 41. France CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 42. UK CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 43. Italy CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 44. Russia CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 45. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size Market Share by Region (2020-2025)
 Figure 46. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size Market Share by Type (2020-2025)
 Figure 47. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size Market Share by Application (2020-2025)
 Figure 48. Egypt CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 49. South Africa CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 50. Israel CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 51. Turkey CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 52. GCC Countries CAR-T Therapy for Hematological Cancer Market Size Growth 2020-2025 ($ millions)
 Figure 53. Americas CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 54. APAC CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 55. Europe CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 56. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 57. United States CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 58. Canada CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 59. Mexico CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 60. Brazil CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 61. China CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 62. Japan CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 63. Korea CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 64. Southeast Asia CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 65. India CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 66. Australia CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 67. Germany CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 68. France CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 69. UK CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 70. Italy CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 71. Russia CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 72. Egypt CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 73. South Africa CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 74. Israel CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 75. Turkey CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)
 Figure 76. Global CAR-T Therapy for Hematological Cancer Market Size Market Share Forecast by Type (2026-2031)
 Figure 77. Global CAR-T Therapy for Hematological Cancer Market Size Market Share Forecast by Application (2026-2031)
 Figure 78. GCC Countries CAR-T Therapy for Hematological Cancer Market Size 2026-2031 ($ millions)

Companies Mentioned

Novartis

Gilead Sciences

Bristol-Myers Squibb

J&J

JW Therapeutics

FOSUNKite

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff